"A Shot In The Arm For Cleveland BioLabs" (Inside Wall Street, Oct. 2, 2006)
In "A shot in the arm for Cleveland BioLabs" (Inside Wall Street, Oct. 2), Curaxins is in phase 2 trials, not phase 3, and has killed human cancer cells transplanted into animals, not primates. And Cleveland Clinic will provide the equivalent of $5 million in research and infrastructure.
Copyright 2006, by The McGraw-Hill Companies Inc. All rights reserved.
Printer-Friendly Version
